dabrafenib,trametinib,pembrolizumab
novartis,merck
['melanoma', 'pembro']
#melanoma orals #asco22 :
neodjuvant concurrent triple therapy (brafi/meki + pembro) for braf-mutant resectable melanoma showed better responses but higher toxicities! neodjuvant ici still safer?! 
Hematology and Medical Oncology fellow at Duke University, Lebanese, husband to the best anesthesiologist, IO fan, trialist and skin cancer specialist to be!